drugset / Trial / NCT00007904
Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes
Phase 2
Completed
16 enrolled
Case Comprehensive Cancer Center
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: This phase II trial is studying how well giving combination chemotherapy together with filgrastim and radiation therapy works in treating patients with stage II or stage IIIA breast cancer.
Timeline
- Start
- 2000-07
- Primary completion
- 2006-06
- Completion
- 2012-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 700 mg/m2 | Intravenous |
| Subject | Doxorubicin | Other / unclassified | — | Intravenous |
| Subject | Paclitaxel | Small molecule | 160 mg/m2 | Intravenous |
| Subject | Tamoxifen | Small molecule | 20 mg | Oral |
| Background | filgrastim | Protein / enzyme biologic | 10 ug/kg | Subcutaneous |